PTC Therapeutics Announces Plans to Resubmit ...
PTC Therapeutics plans to resubmit an NDA for Translarna™ by mid-2024, following FDA feedback. The therapy targets nonsense mutation Duchenne. PPMD supports FDA's review for informed patient decisions, hopeful for approval.
Reference News
PTC Therapeutics Announces Plans to Resubmit ...
PTC Therapeutics plans to resubmit an NDA for Translarna™ by mid-2024, following FDA feedback. The therapy targets nonsense mutation Duchenne. PPMD supports FDA's review for informed patient decisions, hopeful for approval.